BMS registers Phase 1 CAR T cell trial in kidney cancer; adds mavacamten real-world study

Bristol-Myers Squibb registered two new studies in late September 2026, one interventional and one observational.

• A Phase 1 trial of BMS-986527, a healthy donor allogeneic CD70-targeted chimeric antigen receptor (CAR) T cell therapy, is being studied as monotherapy or in combinations in participants with clear cell renal cell carcinoma (ccRCC)¹. The study, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, with Bristol-Myers Squibb as collaborator, is listed as not yet recruiting, with an estimated enrollment of 112 participants¹ and first posted on 2026-09-30.
• An observational study, "Real-world Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy" (REMAP-HCM), sponsored by Bristol-Myers Squibb, aims to describe how mavacamten is used in routine care for Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), including use as monotherapy or with other background/concomitant oHCM medications². It was first posted on 2026-09-29, one day before the CAR T trial, and is not yet recruiting, with an estimated enrollment of 800 participants² at one site in China, Fudan University Zhongshan Hospital, Shanghai, China².